Niagen Bioscience Renames Research Program to Focus on NAD+ Advancements

Niagen Bioscience Inc. (NASDAQ:NAGE) has renamed its research program from the ChromaDex External Research Program (CERP) to the Niagen Research Program, emphasizing a renewed focus on advancing NAD+ applications and scientific understanding.

By Abdul Rahman Fri, June 19, 2026 at 9:20 PM GMT+3 1 min read · Yahoo Finance · June 19, 2026, 18:20 UTC

Niagen Bioscience Renames Research Program to Focus on NAD+ Advancements

Topics: biotech research NAD+ Niagen

Read the full article at Yahoo Finance

More World news

CEZ Reports 9M Revenue Growth and 24% Increase in Net Income Seeking Alpha · November 12, 2026, 15:05 UTC
BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera PR Newswire · November 12, 2026, 15:15 UTC
U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO Seeking Alpha · November 12, 2026, 15:12 UTC
OpenAI Secures $15 Billion in New Funding at $1.25 Trillion Valuation Seeking Alpha · November 12, 2026, 15:13 UTC
Digi International Shares Fall 18% Following Fiscal Q4 Earnings Release Seeking Alpha · November 12, 2026, 15:13 UTC
Pomerantz Law Firm Investigates Artiva Biotherapeutics Following Program Discontinuation and Fatal Safety Events PR Newswire · November 12, 2026, 15:15 UTC
Major Corporate Earnings Scheduled for Release After Thursday Market Close Seeking Alpha · November 12, 2026, 15:00 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC
Ascendis Pharma Reports Strong Q3 2026 Results Driven by Yorvipath Growth Motley Fool · November 12, 2026, 15:09 UTC
Pomerantz Law Firm Investigates Omeros Corporation Following Regulatory Setbacks PR Newswire · November 12, 2026, 15:10 UTC